TG Therapeutics, Inc.
TGTX
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), anā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.00
Price+0.15%
$0.04
1Y
Price
Market Cap
$4.922b
Mid
Price/Earnings 3y Avg5y Avg
11.2x
Premium
Premium
Financials Overview
Key metrics over the past few years+26.7%
EBITDA Margin+20.0%
Net Profit Margin-20.4%
Free Cash Flow MarginRevenue
$454.068m
+38.0%
1y CAGR+2789.6%
3y CAGR+2077.6%
5y CAGREarnings
$60.458m
+158.6%
1y CAGR+116.4%
3y CAGR+98.0%
5y CAGREPS
$0.37
+146.7%
1y CAGR+106.4%
3y CAGR+90.8%
5y CAGRBook Value
$237.289m
$656.689m
Assets$419.400m
Liabilities$254.583m
DebtDebt to Assets
38.8%
2.6x
Debt to EBITDAFree Cash Flow
-$61.095m
-50.6%
1y CAGR+0.8%
3y CAGR+10.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company